113 related articles for article (PubMed ID: 35880672)
1. The association between PI3K, JAK/STAT pathways with the PDL-1 expression in prostate cancer.
Kazan O; Kir G; Culpan M; Cecikoglu GE; Atis G; Yildirim A
Andrologia; 2022 Nov; 54(10):e14541. PubMed ID: 35880672
[TBL] [Abstract][Full Text] [Related]
2. Preclinical development and clinical studies of targeted JAK/STAT combined Anti-PD-1/PD-L1 therapy.
Chen M; Wang S
Int Immunopharmacol; 2024 Mar; 130():111717. PubMed ID: 38387193
[TBL] [Abstract][Full Text] [Related]
3. The prognostic role of immune checkpoint markers programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) in a large, multicenter prostate cancer cohort.
Ness N; Andersen S; Khanehkenari MR; Nordbakken CV; Valkov A; Paulsen EE; Nordby Y; Bremnes RM; Donnem T; Busund LT; Richardsen E
Oncotarget; 2017 Apr; 8(16):26789-26801. PubMed ID: 28460462
[TBL] [Abstract][Full Text] [Related]
4. Correlation analysis of JAK-STAT pathway components on prognosis of patients with prostate cancer.
Liu X; He Z; Li CH; Huang G; Ding C; Liu H
Pathol Oncol Res; 2012 Jan; 18(1):17-23. PubMed ID: 21681602
[TBL] [Abstract][Full Text] [Related]
5. Effect of baricitinib in regulating programmed death 1 and ligand programmed cell death ligand 1 through JAK/STAT pathway in psoriasis.
Deepak HB; Prince SE; Deshpande P
Indian J Pharmacol; 2022; 54(3):183-193. PubMed ID: 35848689
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemistry of immune checkpoint markers PD-1 and PD-L1 in prostate cancer.
Sharma M; Yang Z; Miyamoto H
Medicine (Baltimore); 2019 Sep; 98(38):e17257. PubMed ID: 31567999
[TBL] [Abstract][Full Text] [Related]
7. Biparametric Prostate Imaging Reporting and Data System version2 and International Society of Urological Pathology Grade Predict Biochemical Recurrence after Radical Prostatectomy.
Takeuchi N; Sakamoto S; Nishiyama A; Horikoshi T; Yamada Y; Iizuka J; Maimaiti M; Imamura Y; Kawamura K; Imamoto T; Komiya A; Ikehara Y; Akakura K; Ichikawa T
Clin Genitourin Cancer; 2018 Aug; 16(4):e817-e829. PubMed ID: 29576444
[TBL] [Abstract][Full Text] [Related]
8. Complex interactions between the components of the PI3K/AKT/mTOR pathway, and with components of MAPK, JAK/STAT and Notch-1 pathways, indicate their involvement in meningioma development.
El-Habr EA; Levidou G; Trigka EA; Sakalidou J; Piperi C; Chatziandreou I; Spyropoulou A; Soldatos R; Tomara G; Petraki K; Samaras V; Zisakis A; Varsos V; Vrettakos G; Boviatsis E; Patsouris E; Saetta AA; Korkolopoulou P
Virchows Arch; 2014 Oct; 465(4):473-85. PubMed ID: 25146167
[TBL] [Abstract][Full Text] [Related]
9. Prediction of biochemical recurrence after robot-assisted radical prostatectomy: analysis of 784 Japanese patients.
Hashimoto T; Yoshioka K; Nagao G; Nakagami Y; Ohno Y; Horiguchi Y; Namiki K; Nakashima J; Tachibana M
Int J Urol; 2015 Feb; 22(2):188-93. PubMed ID: 25339062
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 expression is mainly regulated by interferon gamma associated with JAK-STAT pathway in gastric cancer.
Mimura K; Teh JL; Okayama H; Shiraishi K; Kua LF; Koh V; Smoot DT; Ashktorab H; Oike T; Suzuki Y; Fazreen Z; Asuncion BR; Shabbir A; Yong WP; So J; Soong R; Kono K
Cancer Sci; 2018 Jan; 109(1):43-53. PubMed ID: 29034543
[TBL] [Abstract][Full Text] [Related]
11. Immune Characterization of the Programmed Death Receptor Pathway in High Risk Prostate Cancer.
Baas W; Gershburg S; Dynda D; Delfino K; Robinson K; Nie D; Yearley JH; Alanee S
Clin Genitourin Cancer; 2017 Oct; 15(5):577-581. PubMed ID: 28461179
[TBL] [Abstract][Full Text] [Related]
12. JAK/STAT signal pathway activation promotes progression and survival of human oesophageal squamous cell carcinoma.
You Z; Xu D; Ji J; Guo W; Zhu W; He J
Clin Transl Oncol; 2012 Feb; 14(2):143-9. PubMed ID: 22301404
[TBL] [Abstract][Full Text] [Related]
13. The roles of PD-1/PD-L1 in the prognosis and immunotherapy of prostate cancer.
Xu Y; Song G; Xie S; Jiang W; Chen X; Chu M; Hu X; Wang ZW
Mol Ther; 2021 Jun; 29(6):1958-1969. PubMed ID: 33932597
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Risk of Clinical Progression Utilizing Magnetic Resonance Imaging Findings of Locally Recurrent Prostate Cancer in Patients with Biochemical Recurrence following Radical Prostatectomy.
Tanaka T; Kawashima A; Rangel LJ; Schulte PJ; Froemming AT; King BF; Mynderse LA; Karnes RJ
J Urol; 2022 May; 207(5):1038-1047. PubMed ID: 34981952
[TBL] [Abstract][Full Text] [Related]
15. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance and risk factors of International Society of Urological Pathology (ISUP) grade upgrading in prostate cancer patients undergoing robot-assisted radical prostatectomy.
Takeshima Y; Yamada Y; Teshima T; Fujimura T; Kakutani S; Hakozaki Y; Kimura N; Akiyama Y; Sato Y; Kawai T; Yamada D; Kume H
BMC Cancer; 2021 May; 21(1):501. PubMed ID: 33947348
[TBL] [Abstract][Full Text] [Related]
17. Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance.
Martin AM; Nirschl TR; Nirschl CJ; Francica BJ; Kochel CM; van Bokhoven A; Meeker AK; Lucia MS; Anders RA; DeMarzo AM; Drake CG
Prostate Cancer Prostatic Dis; 2015 Dec; 18(4):325-32. PubMed ID: 26260996
[TBL] [Abstract][Full Text] [Related]
18. Do Ultrasensitive Prostate Specific Antigen Measurements Have a Role in Predicting Long-Term Biochemical Recurrence-Free Survival in Men after Radical Prostatectomy?
Sokoll LJ; Zhang Z; Chan DW; Reese AC; Bivalacqua TJ; Partin AW; Walsh PC
J Urol; 2016 Feb; 195(2):330-6. PubMed ID: 26307160
[TBL] [Abstract][Full Text] [Related]
19. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
Kupelian PA; Katcher J; Levin HS; Klein EA
Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
[TBL] [Abstract][Full Text] [Related]
20. Tumor-regulated macrophage type 2 differentiation promotes immunosuppression in laryngeal squamous cell carcinoma.
Zhang P; Zhang Y; Wang L; Lou W
Life Sci; 2021 Feb; 267():118798. PubMed ID: 33220295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
